For more information or confidential assistance
800-306-3180
se habla español

FDA Updates Invokana Label Regarding Bone Fracture Risk

The U.S. Food and Drug Administration (FDA) has released a new drug safety communication regarding Invokana and Invokamet (canagliflozin). The safety announcement, which was released on September 10, 2015, adds a new warning to the drug’s label and updates the adverse reactions section with regard to the risk of bone... Read more »

Report Highlights Diabetic Ketoacidosis Risk Factors for SGLT2 Inhibitor Patients

Earlier this year, the U.S. Food and Drug Administration (FDA) published a safety communication that alerts consumers about an increased risk of diabetic ketoacidosis (DKA) with the use of sodium–glucose cotransporter 2 (SGLT2) inhibitors, including Invokana, Invokamet, Farxiga, Jardiance and others. Diabetic ketoacidosis is a potentially life-threatening complication of diabetes... Read more »

Research Into Safer Alternatives to Statins

Cholesterol-lowering statins are among world’s most widely prescribed drugs, but concerns about Lipitor side effects, including the increased risk for Type 2 diabetes, has fueled a wave of litigation and further research on safer alternatives. As reported by the New York Times, a new study has found another type of... Read more »